Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Trial ID or NCT#
Phase I study of SPARC1023 alone and in combination with carboplatin
Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
- - Age ≥18 years - ECOG Performance Status ≤ 1. - Estimated life expectancy of at least 12-weeks; - Measurable disease as per RECIST guideline (Version 1.1);
- - Any malignancy within past 5-years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer - Known hypersensitivity to the study drugs - Treatment with any anti-cancer agents within 28 days of study entry - Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy
George A. Fisher Jr.
Medical oncologist, Gastrointestinal specialist
Colleen Haas Chair in the School of Medicine
Contact us to find out if this trial is right for you.
View on ClinicalTrials.gov